Compare T-Rex 2X Inverse MSTR Daily Target ETF (MSTZ) vs Pfizer Inc (PFE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
T-Rex 2X Inverse MSTR Daily Target ETF vs Pfizer Inc — how do they compare? T-Rex 2X Inverse MSTR Daily Target ETF trades at $2.55 (market cap $94.46M), while Pfizer Inc trades at $28.16 (market cap $158.56B). The key difference: Pfizer Inc is far larger — about 1678.6× T-Rex 2X Inverse MSTR Daily Target ETF's market cap, and Pfizer Inc pays a 6.18% dividend while T-Rex 2X Inverse MSTR Daily Target ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold T-Rex 2X Inverse MSTR Daily Target ETF for 8 Days and Pfizer Inc for 158 Days on average.
| MSTZ | PFE | |
|---|---|---|
Market Cap | $94.46M | $158.56B |
Volume | 104,717,733 | 44,138,282 |
Sector | Leveraged / Inverse | Health |
52-Week High | $27.92 | $29.02 |
52-Week Low | $2.29 | $23.67 |
Typical Hold Time | 8 Days | 158 Days |
Enterprise Value | — | $210.06B |
Dividend Yield | — | 6.18% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
MSTZ is trading at $2.54, down 4.51% today, with technical indicators showing a bearish trend as moving averages signal selling pressure. The stock lacks key financial ratio data, making fundamental assessment challenging. Recent ETF coverage highlights its inclusion in leveraged/inverse ETF discussions, though specific company performance details are limited.
The outlook remains cautious due to incomplete financial disclosures and bearish technical signals. Investment opportunities depend on forthcoming earnings clarity, while risks include volatility from limited institutional coverage and market sentiment shifts. Investors should await detailed financial updates for informed decisions.
Pfizer (PFE) trades at $28.00, up 1.87% on the day, with a bullish technical signal from moving averages. The company reported revenue of $62.58 billion in 2025 with a net income margin of 6.8%, and has beaten EPS estimates for the last three quarters. Recent news highlights Pfizer's focus on its obesity and oncology pipeline as key growth drivers in 2026.
The stock presents a value opportunity with a consensus price target of $29.17, but faces risks from patent expirations and projected earnings decline. Investor sentiment is mixed, with analysts largely neutral, emphasizing the stock's defensive cash flow and dividend yield amid ongoing business transformation.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About T-Rex 2X Inverse MSTR Daily Target ETF
MSTZ is a leveraged ETF that seeks daily investment results corresponding to 200% of the inverse (opposite) of the daily performance of the MicroStrategy Incorporated (MSTR) stock. It is designed as a tactical tool for experienced traders to take a bearish position on MSTR, a company known for its large Bitcoin holdings. Due to the effects of compounding and leverage, the ETF is intended to be held for a single day and is not suitable for long-term investment, as its performance over longer periods may significantly deviate from its stated daily objective.
Read more on MSTZ →About Pfizer Inc
Pfizer Inc. operates as a pharmaceutical company. The Company offers medicines, vaccines, medical devices, and consumer healthcare products for oncology, inflammation, cardiovascular, and other therapeutic areas. Pfizer serves customers worldwide.
Read more on PFE →
